Literature DB >> 32729298

The prognostic relationship between histopathological and immunohistochemical features of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed type.

Fatmagül Çabuk1, Nuray Başsüllü1, İlknur Türkmen1, Murat Dayangaç2, Murat Akyıldız3, Yıldıray Yüzer2, Yaman Tokat2, Gülen Doğusoy1.   

Abstract

Hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular and cholangiocarcinoma are the most common cancers of the liver. In this study, our first aim is to evaluate the relationship between prognosis and clinicopathological parameters. The second aim involves investigating the need for immunohistochemical staining and patterns of tumours to differentiate between them. Sixty-one cases were included in this study. For IHC, we used Hep par-1, CK7, CK19, CD56 and p53 staining, and the patterns of tumours were evaluated in haematoyxylin-eosin sections. No significant differences were found in Kaplan-Meier life analysis between the tumour types and OS and DFS values, but these values were greater in HCC than in ICC. There were no relationships between clinicopathologic parameters and OS and DFS. Although the multifocality, stage and grade of tumour were higher in HCC than in ICC, the perineural invasion and lymph node metastasis were more common in ICC than in HCC. The diagnosis was changed in 4 cases, from HCC to ICC in one case and to combined type in 3 cases after IHC. Pathologist should be alert to mixed patterns in terms of diagnosis and IHC, because it helps differential diagnosis in these cases.

Entities:  

Keywords:  cholangiocarcinoma; liver neoplasms; risk factors.; hepatocellular carcinoma

Mesh:

Year:  2020        PMID: 32729298     DOI: 10.5114/pjp.2020.97015

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  1 in total

1.  A New Clinical Nomogram From the TCGA Database to Predict the Prognosis of Hepatocellular Carcinoma.

Authors:  Dingde Ye; Jiamu Qu; Jian Wang; Guoqiang Li; Beicheng Sun; Qingxiang Xu
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.